Dataset Information

Dendritic cell vaccine induces antigen-specific CD8⁺ T cells that are metabolically distinct from those of peptide vaccine and is well-combined with PD-1 checkpoint blockade.

ABSTRACT: The success of immune checkpoint blockade has unequivocally demonstrated that anti-tumor immunity plays a pivotal role in cancer therapy. Because endogenous tumor-specific T-cell responsiveness is essential for the success of checkpoint blockade, combination therapy with cancer vaccination may facilitate tumor rejection. To select the best vaccine strategy to combine with checkpoint blockade, we compared dendritic cell-based vaccines (DC-V) with peptide vaccines for induction of anti-tumor immunity that could overcome tumor-induced immunosuppression. Using B16 melanoma and B16-specific TCR-transgenic T-cells (pmel-1), we found that DC-V efficiently primed and expanded pmel-1 cells with an active effector and central memory phenotype that were not exhausted. Vaccine-primed cells were metabo

SUBMITTER: Nagaoka K

PROVIDER: S-EPMC5790382 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

ACCESS DATA

Dataset Information

Dendritic cell vaccine induces antigen-specific CD8⁺ T cells that are metabolically distinct from those of peptide vaccine and is well-combined with PD-1 checkpoint blockade.

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

Dendritic cell vaccine induces antigen-specific CD8+ T cells that are metabolically distinct from those of peptide vaccine and is well-combined with PD-1 checkpoint blockade.

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dendritic cell vaccine induces antigen-specific CD8⁺ T cells that are metabolically distinct from those of peptide vaccine and is well-combined with PD-1 checkpoint blockade.